NextGen Jane
Genomics company analyzing endometrial tissue and menstrual blood for reproductive health.
What they do
The company utilizes custom collection tampons to gather menstrual blood for clinical analysis. By tracking genomic markers in shed endometrial tissue, the technology aims to identify conditions such as endometriosis and uterine fibroids non-invasively, providing a diagnostic alternative to laparoscopy.
The record
- Vertical
- Women's Health
- Sub-segment
- Menstrual blood diagnostics
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- Oakland, USA
- Region
- North America
- Founded
- 2014
- Total funding
- $9M raised
Notable investors: Material Impact, Viking Global Investors, Jane Martin.